Related Experiment Videos
[Antitumor activity of cytostatics on a newly transplanted tumor in mice, myosarcoma ISM]
Abstract:
The author examined the action of 14 known antitumor preparations on mice BAIB/c with newly transplanted tumour occurred after induction with tetrachlormethane. The tumour myosarcoma ISM showed high sensitivity to cyclophosphamide, administration of which caused complete inhibition of tumour growth and regression of tumours. A comparative high antitumour effect was found after usage of sarcolysine, brunemycine and mitomycine C (over 70% of inhibition). There was a moderately manifested inhibition of the tumour growth (around 50%) after administration of cytostatics degranol, purinetol, 5-fluorouracyl and ftorafur. The substances alexan, rubomycine and 1-(2-chlorethy)-3-cyclohexyl-1-nitrosourea were without effect on myosarcom ISM. The obtained data showed that then tumour well differentiated substances in accordance with their action. It is a prorer model for thorough investigation of antitumour substances.
Insights
This study evaluated 14 antitumor drugs against mouse myosarcoma ISM. Cyclophosphamide completely inhibited tumor growth, while sarcolysine, brunemycine, and mitomycin C showed high efficacy.
Area of Science:
- Oncology
- Pharmacology
Background:
- The development of effective antitumor agents is crucial for cancer treatment.
- Evaluating novel and existing compounds against specific tumor models aids in drug discovery.
Purpose of the Study:
- To assess the efficacy of 14 known antitumor preparations against a newly induced mouse myosarcoma.
- To identify potent chemotherapeutic agents for myosarcoma ISM.
Main Methods:
- Induction of myosarcoma ISM in BAIB/c mice using tetrachlormethane.
- Administration of 14 different antitumor preparations to tumor-bearing mice.
- Evaluation of tumor growth inhibition and regression as efficacy indicators.
Main Results:
- Cyclophosphamide demonstrated complete inhibition of tumor growth and regression.
- Sarcolysine, brunemycine, and mitomycin C exhibited significant antitumor effects (>70% inhibition).
- Degranol, purinetol, 5-fluorouracil, and ftorafur showed moderate inhibition (approx. 50%), while alexan, rubomycine, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea were ineffective.
Conclusions:
- Myosarcoma ISM is sensitive to specific antitumor agents, notably cyclophosphamide.
- The study validates the myosarcoma ISM model for screening and differentiating the action of antitumor substances.
- Findings support the potential of certain cytostatics in managing this specific tumor type.